SCHEMBL4717907

SCHEMBL4717907

COc1cc2ncnc(N3CCCCc4ccccc43)c2cc1OC

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 8/20 0.85
CSF1R P07333 1/20 0.83
KIT P10721 2/20 0.69
RET P07949 2/20 0.66
KDR P35968 2/20 0.62
KIF5B P33176 1/20 0.62
TUBB4A P04350 1/20 0.57
TUBB P07437 1/20 0.57
PDGFRB P09619 1/20 0.57
TUBA3C P0DPH7 1/20 0.57
TUBA1B P68363 1/20 0.57
TUBA4A P68366 1/20 0.57
TUBB4B P68371 1/20 0.57
TUBB3 Q13509 1/20 0.57
TUBB2A Q13885 1/20 0.57
TUBB8 Q3ZCM7 1/20 0.57
TUBA3E Q6PEY2 1/20 0.57
TUBA1A Q71U36 1/20 0.57
TUBA1C Q9BQE3 1/20 0.57
TUBB6 Q9BUF5 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9112738 0.99 EGFR (0.83) EGFRCSF1RKITRETKDR
SCHEMBL4719788 0.97 EGFR (0.87) EGFRCSF1RKITRETKDR
Hydrochloric Acid SCHEMBL6180077 0.95 EGFR (0.87) EGFRCSF1RKITRETKDR
SCHEMBL8647346 0.93 EGFR (0.74) EGFRCSF1RKITRETKDR
SCHEMBL6185124 0.92 EGFR (1.00) EGFRCSF1RKITRETKDR
Hydrochloric Acid SCHEMBL6179838 0.91 EGFR (1.00) EGFRCSF1RKITRETKDR
SCHEMBL8646148 0.86 EGFR (0.70) EGFRCSF1RKITRETKDR
SCHEMBL4759922 0.86 EGFR (0.63) EGFRCSF1RKITRETKDR
SCHEMBL4761475 0.83 EGFR (0.65) EGFRCSF1RKITRETKDR
SCHEMBL8648516 0.83 EGFR (0.65) EGFRCSF1RKITRETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940819-A1 PHOSPHODIESTERASE 10 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-07-09 EP claimed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 US claimed
WO-2007022280-A1 PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-02-22 WO claimed
EP-1940819-A1 PHOSPHODIESTERASE 10 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-07-09 EP disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 US disclosed
WO-2007022280-A1 PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-02-22 WO disclosed
WO-1995023141-A1 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS PFIZER INC. (US) 1995-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093515-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE12, PDE10A EGFR 4754/4885CSF1R 4142/4885KIT 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.